Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Nectar Lifesciences Ltd

NECLIFE.NS ✓ COMPLIANT ☆ Track — members

NSE India · Healthcare · Pharmaceuticals ·

India Micro Cap Analyst: N/A

Last Close

$0.12

▼ -3.00%

Market Cap $22.39M · Vol 315.03K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$22.39M

Micro Cap

Div Yield

N/A

Annual dividend

EPS Growth

N/A

YoY

RSI (14)

61.39

Momentum

Beta

1.56

vs Market

52W High

$0.23

53.99% below

52W Low

$0.10

16.93% above

Volume

315.03K

Avg 123.32K

P/B

0.31

Price-to-book

ROE

1.97%

Return on equity

Free Float

44.34%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Nectar Lifesciences Ltd (NECLIFE.NS) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does NECLIFE.NS pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+3.97%

-1.70%

-13.73%

-17.91%

YTD

-43.33%

-24.24%

-61.19%

-64.52%

Financials & Valuation

TTM · Annual

Total Revenue	$215.13K
Net Income	$-6,136,223.00
Revenue Growth (YoY)	-99.84%
Gross Margin	82.96%
Operating Margin	-2,936.29%
Net Profit Margin	-2,852.39%
ROE	1.97%
ROA · ROIC	-6.59% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	101.11
P/B	0.31
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	194.26M

Technical Indicators

50-Day SMA	$0.12
200-Day SMA	$0.14
RSI (14)	61.39
Beta	1.56
52-Week High	$0.23
52-Week Low	$0.10

Volume Today	315.03K
Avg Daily Volume (30D)	123.32K
Relative Volume	2.55x
Volatility (10D)	34.42
Volatility (30D)	28.58
Free Float	44.34%

Analyst Consensus

N/A

Current Price $0.12

Mean Target N/A

52W Low$0.10 52W High$0.23

Current

Target

$0.10 $0.23

Current Analyst target

· 0 analysts

Identifiers

ExchangeNSE India

FIGIBBG001SMHNJ9

ISININE023H01027

CountryIndia

Sub-IndustryGeneric Pharmaceuticals

Earnings DateN/A

TypeStocks

Instrument TypeFULLPAID Fully Paid Ordinary

Similar Halal Stocks

SUNPHARMA.NS Sun Pharmaceutical Industries Ltd -0.10% 4578.T Otsuka Holdings Co Ltd -3.26% CIPLA.NS Cipla Ltd -0.60% ZYDUSLIFE.NS Zydus Lifesciences Ltd -2.75% RICHTER.BU Richter Gedeon Vegyeszeti Gyar Nyrt +1.56%

Company Profile

Nectar Lifesciences Limited is an India-based pharmaceutical company. The Company's business areas include active pharmaceutical ingredients (APIs) and intermediates, formulations/finished dosage formulations (FDF), menthol and mint derivatives, and empty hard gelatin capsules. The Company is engaged in the manufacturing of oral and sterile cephalosporin products. Its oral cephalosporins include cefixime, cefurozime axetil crystalline, cefuroxime axetil amorphous, cedpodoxime proxetil, cefprozil and cefdinir. Its sterile cephalosporins include cefotaxime sodium, ceftriaxone sodium, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate and cefepime arginine. Its capacities include cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium and ceftriaxone sodium. The Company offers contract manufacturing capabilities for solid dosage forms, such as tablets, capsules, dry powder oral suspension and granules and injectable for cephalosporins.